Illumina plans to lower its yearly running costs by approximately $100m over the course of 2023, with reductions in headcount accounting for most of the planned savings, according to a 21 June 8K report filed with the US Securities and Exchange Commission.
More Kerfuffle At Illumina. This Time, It Is Job Cuts
The company is shrinking its work force and real estate footprint in a bid to save money.
More from Business
• By
Abbott presented late-breaking data at the 2025 American College of Cardiology conference demonstrating that TriClip transcatheter edge-to-edge repair offers prolonged patient benefits compared to medical treatment alone after two years, which were not evident at one year.
• By
The Cologuard Plus test has a sensitivity of 95% and a specificity of 94% for the detection of colorectal cancer; “unmatched accuracy,” according to Exact Sciences.
• By
Leann Sims joins AbundaBox as COO; Oura Ring firm appoints CMO.
More from Medtech Insight
• By
Beyond the US market, Monogram is actively pursuing regulatory approvals abroad, with India as a key target. The company has partnered with Shalby Hospitals, one of India’s largest orthopedic hospital networks, to conduct clinical trials and accelerate regulatory clearance in the region.
• By
In an interview with Medtech Insight, Dexcom’s COO Jake Leach and Adrian Gut, senior director international access, discuss the company’s global expansion, the role of AI in diabetes management, the challenges of securing reimbursement, and how regulators are influencing the future of CGM technology.